Watchlist Price Alert

Mineralys Therapeutics In... (MLYS)

NASDAQ: MLYS · Real-Time Price · USD

13.80

0.35 (2.60%)

At close: Jun 17, 2025, 3:59 PM

13.99

1.34%

Pre-market: Jun 18, 2025, 07:02 AM EDT

Mineralys Therapeutics Balance Sheet Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q1 2022	Q4 2021
Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Mar 31, 2022	Dec 31, 2021
Cash & Equivalents	165.01M	114.09M	97.27M	67.86M	90.42M	49.3M	265.89M	101.14M	138.25M	87.7M	48.95M	-10.61M	10.61M
Short-Term Investments	n/a	84.1M	166.33M	243.26M	248.15M	187.26M	167.46M	159.96M	132.39M	22.41M	72M	21.22M	n/a
Long-Term Investments	n/a	n/a	n/a	n/a	n/a	2.48M	12.13M	21.68M	31.12M	n/a	n/a	n/a	n/a
Other Long-Term Assets	397K	499K	452K	449K	379K	51K	51K	51K	39K	4.33M	564K	-10.61M	3K
Receivables	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Inventory	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Current Assets	189.5M	7.16M	n/a	6.89M	8.25M	12.54M	11.61M	8.39M	4.63M	2.7M	n/a	n/a	n/a
Total Current Assets	354.51M	205.35M	267.73M	318M	346.82M	249.1M	265.38M	269.49M	275.27M	110.11M	121.89M	10.61M	11.12M
Property-Plant & Equipment	38K	53K	69K	42K	51K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Goodwill & Intangibles	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Total Long-Term Assets	435K	552K	521K	491K	430K	2.53M	12.18M	21.73M	31.16M	4.33M	564K	-10.61M	3K
Total Assets	354.94M	205.9M	268.25M	318.49M	347.25M	251.64M	277.56M	291.22M	306.44M	114.44M	122.45M	n/a	11.13M
Account Payables	373K	479K	3.11M	1.71M	4.26M	601K	5.57M	2.2M	2.39M	1.91M	2.56M	n/a	763K
Deferred Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Short-Term Debt	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Current Liabilities	13.01M	3.58M	28.21M	n/a	n/a	n/a	6.75M	n/a	381K	n/a	n/a	n/a	n/a
Total Current Liabilities	13.39M	14.65M	31.32M	28.4M	19.2M	10.48M	13.54M	6.21M	10.56M	8.07M	7.22M	n/a	5.05M
Long-Term Debt	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Long-Term Liabilities	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	158.64M	n/a	n/a
Total Long-Term Liabilities	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	158.64M	158.64M	n/a	29M
Total Liabilities	13.39M	14.65M	31.32M	28.4M	19.2M	10.48M	13.54M	6.21M	10.56M	166.71M	165.86M	n/a	34.05M
Total Debt	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Common Stock	6K	5K	5K	5K	5K	4K	4K	4K	4K	1K	1K	n/a	1K
Retained Earnings	-344.73M	-302.52M	-253.57M	-197.23M	-156.22M	-124.71M	-100.32M	-77.56M	-65.42M	-52.81M	-43.74M	n/a	-23.01M
Comprehensive Income	n/a	n/a	n/a	0.00	0.00	-251.64M	-277.56M	-0.00	n/a	-158.64M	n/a	-22.93M	-0.00
Shareholders Equity	341.56M	191.26M	236.93M	290.1M	328.05M	241.15M	264.01M	285.01M	295.88M	-52.27M	-43.41M	6.07M	-22.93M
Total Investments	n/a	84.1M	166.33M	243.26M	248.15M	189.75M	12.13M	181.63M	163.51M	22.41M	72M	21.22M	n/a